We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lyo-Ready PCR Reagents Make Ultra-Sensitive Diagnostics Development Painless

By LabMedica International staff writers
Posted on 12 Apr 2022

Molecular diagnostics have traditionally relied on ‘wet’ reagents, necessitating costly temperature-controlled transport and on-site cold storage at the point of test use. More...

Diagnostics developers are increasingly looking to use lyophilized test formats to circumvent these challenges and develop more compact, lighter, and shelf-stable assays. However, developing lyophilized diagnostics is complex — traditional reagent mixes contain lyophilization-incompatible components such as glycerol, and concerns can often arise around test sensitivity after reagents are resuspended. Now, newly-launched reagents come already optimized for freeze-drying, meaning diagnostic developers only need to add their desired probes and primers prior to lyophilization, unlocking smoother, faster test development. Importantly, the new reagents are pre-blended with a unique mix of excipients to ensure uncompromised sensitivity after resuspension - even for multiple RNA targets - making the reagents ideal for high-performance multiplex tests.

PCR Biosystems Ltd. (London, UK) has launched the Lyo-Ready Probe 1-Step Kit, a lyophilizable 4x RT-qPCR reagent mix designed for ultra-sensitive high-throughput detection of RNA sequences. The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format. As a result, simplified creation of freeze-dried multiplex assays with lower limits of detection will be possible, and the logistical and storage infrastructure required to deliver tests to the point of use will be streamlined. Diagnostic developers can thus accelerate their time to market, and a broader swathe of clinical, veterinary, food and environmental testing end-users will be able to benefit from superior nucleic acid detection.

The lyo-ready kits contain a glycerol-free 4x qPCR mix, high-concentration thermostable UltraScript Reverse Transcriptase for superior sensitivity and accuracy, and a blend of excipients that confer identical performance pre- and post-drying. As with PCR Biosystems’ other 1-step RT-qPCR kits, the new mixes include the company’s proprietary hot start Taq polymerase for specific template amplification, and advanced buffer chemistry including magnesium and dNTPs. The reagent mixes have been validated for the qualitative detection of SARS-CoV-2 as well as the most common respiratory viruses, including influenza and respiratory syncytial virus. As such, the new reagent formulations are perfectly suited for the creation of multiplex winter panel diagnostic kits.

“With all our PCR reagents, we’ve done the hard work to make ultra-sensitive diagnostics development as painless as possible,” said Alex Wilson, co-founder of PCR Biosystems. “For lyophilised multiplex assays, that means creating a reagent mix that’s ready for freeze-drying right out of the packet, and capable of retaining exceptionally low limits of detection. On top of this, customers also benefit from the PCR Biosystems edge - free evaluation samples, agile technical support, and tailored product customization options.”

Related Links:
PCR Biosystems Ltd. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.